Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data SOPHiA GENETICS SA files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
25.4
28.4
40.5
47.6
62.4
65.2
77.3
Cost of revenue
7.53
10.7
15.2
16.3
19.5
21.2
25.2
Gross profit
17.8
17.7
25.2
31.3
42.9
43.9
52.1
Research and development
15
18.6
26.6
35.4
37
34.4
34.2
General and administrative
2.77
2.01
5.33
6.64
Operating income
-37.4
-71.5
-87.8
-74.8
-66.6
-70.9
Pre-tax income
-33.6
-41.2
-73.5
-87.6
-78.5
-61.3
-77.5
Income tax
0.16
-1.89
0.17
-0.14
0.49
1.22
1.51
Net income
-33.8
-39.3
-73.7
-87.4
-79
-62.5
-79
EPS, basic
-0.93
-1.33
-1.36
-1.22
-0.95
-1.17
EPS, diluted
-0.93
-1.33
-1.36
-1.22
-0.95
-1.17
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
18.1
74.6
193
161
123
80.2
70.3
Receivables
6.36
6.28
6.65
13.6
7.44
15
Inventory
3.38
5.73
5.16
6.48
5.87
6.35
Total current assets
110
283
196
148
99.4
99.1
Property, plant and equipment
1.77
4.66
7.13
7.47
5.21
5.67
Lease right-of-use assets
4.54
3.77
11.3
14.3
15.6
14.2
12.4
Intangible assets
13.3
15.7
20
27.2
29
35.9
Total assets
132
320
244
206
155
163
Short-term debt
2.87
Total current liabilities
21.6
28.6
26.8
35.6
26.8
50.5
Lease liabilities
2.88
11.2
14.1
15.7
14.6
12.6
Total liabilities
31.6
44.8
43.7
54.7
58.8
116
Total debt
3.84
3.33
0
Paid-in capital
227
471
472
472
472
474
Retained earnings
-138
-211
-299
-378
-440
-519
Total equity
22.3
101
275
200
151
96.5
47.1
Total liabilities and equity
132
320
244
206
155
163
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-33.8
-39.3
-73.7
-87.4
-79
-62.5
-79
Cash from operations
-31.7
-31.7
-57.9
-70.1
-53.2
-44.5
-35.9
Capital expenditures
-1.36
-0.45
-2.68
-4.1
-1.49
-0.24
-0.57
Cash from investing
-3.03
-24.3
-56.9
42
13
-4.76
-8.67
Debt issued
15.8
0
0
0
13.9
34.6
Debt repaid
-1.97
-16.5
-3.17
0
0
Stock issued
108
0
0
0
0
1.09
Cash from financing
-1.02
107
238
-1.57
-2.82
9.86
30.2
Exchange rate effect
-0.1
5.56
-4.56
-1.97
5.02
-3.61
4.45
Free cash flow
-33
-32.2
-60.6
-74.2
-54.7
-44.8
-36.5
Interest paid
0.84
0.86
0.29
0.27
0.01
1.73
Income taxes paid
0.25
-0.15
0.06
0
0.8
0.54
0.2
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $8.34 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
67.4%
Gross profit / revenue.
Operating margin
-91.8%
Operating income / revenue.
Pre-tax margin
-100.3%
Pre-tax income / revenue.
Net margin
-102.2%
Net income / revenue.
FCF margin
-47.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-46.5%
Cash from operations / revenue.
Return on assets (ROA)
-49.6%
Net income / average total assets.
R&D / revenue
44.3%
Research and development expense / revenue.
Capex / revenue
0.7%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
18.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
17.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
22.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
18.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
18.6%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
24.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
5.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-12.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
4.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.96x
Current assets / current liabilities.
Quick ratio
1.69x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.39x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
71.1%
Total liabilities / total assets.
Working capital
$48.6M
Current assets - current liabilities.
Goodwill and intangibles / assets
22.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.49x
Revenue / average total assets.
Fixed asset turnover
14.2x
Revenue / average property, plant and equipment.
Inventory turnover
4.12x
Cost of revenue / average inventory.
Days inventory
89 days
365 x average inventory / cost of revenue.
Receivables turnover
6.89x
Revenue / average receivables.
Days sales outstanding
53 days
365 x average receivables / revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.17
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$1.17
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$710.0M
Share price x shares outstanding.
Enterprise value
$639.7M
Market cap + total debt - cash - short-term investments.
P/S
9.19x
Market cap / revenue.
EV/Sales
8.28x
Enterprise value / revenue.
FCF yield
-5.1%
Free cash flow / market cap.
Earnings yield
-11.1%
Net income / market cap (the inverse of P/E).
What was SOPHiA GENETICS SA's revenue in fiscal 2025?
SOPHiA GENETICS SA reported revenue of $77.3M for fiscal 2025, 18.6% higher than the year before.
Was SOPHiA GENETICS SA profitable in fiscal 2025?
No. It reported a net loss of $79.0M.
How much free cash flow did SOPHiA GENETICS SA generate in fiscal 2025?
Cash from operations of $35.9M minus capital expenditures of $574.0K left free cash flow of -$36.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.